Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
2026Canyon Akromis, Lorraine Li, Kwon Mok Ko et al.
preprint
This project is a secondary analysis of data from Psilocybin in Depression Resistant to Standard Treatments (PsiDeR) study, a phase II, randomised, placebo-controlled clinical trial where participants with treatment resistant depression received either 25 mg of psilocybin or a placebo alongside psychotherapy. This research seeks to determine whether the therapeutic alliance, measured by the...